Cardiovascular drugs rise near top in Open Payments

Candace Stuart | | Cardiovascular Business | Economics

Drug makers Bristol-Myers Squibb and Pfizer spent almost $8 million to promote the novel oral anticoagulant Eliquis to physicians, according to an analysis by ProPublica of the Open Payments database. Eliquis, or apixaban, was the second highest drug on the spending list, with AstraZeneca’s Brilinta (ticagrelor) placing third.

The diabetes drug Victoza by Novo Nordisk ranked first. The analysis appeared in the New York Times “Upshot” section.

Analyzing drugs that are most promoted to doctors

Candace Stuart, Contributor

Related Content

Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access
Abbott opens CGM sensor manufacturing facility in Ireland as part of $465M investment
Eko Health’s AI platform for digital stethoscopes granted new CPT code
Cardiologist demand is on the rise—can hospitals keep up?
Cardiologist receives 35 months in prison for health insurance fraud

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."